JP5022554B2 - アルツハイマー病の生前診断ならびにアミロイド沈着物のインビボ画像化および予防に用いるためのチオフラビン誘導体 - Google Patents

アルツハイマー病の生前診断ならびにアミロイド沈着物のインビボ画像化および予防に用いるためのチオフラビン誘導体 Download PDF

Info

Publication number
JP5022554B2
JP5022554B2 JP2002521434A JP2002521434A JP5022554B2 JP 5022554 B2 JP5022554 B2 JP 5022554B2 JP 2002521434 A JP2002521434 A JP 2002521434A JP 2002521434 A JP2002521434 A JP 2002521434A JP 5022554 B2 JP5022554 B2 JP 5022554B2
Authority
JP
Japan
Prior art keywords
embedded image
amyloid
compound
brain
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002521434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004506723A (ja
JP2004506723A5 (enExample
Inventor
ウィリアム イー． クランク
チェスター エイ． ジュニア マティス
ヤンミン ワン
Original Assignee
ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション filed Critical ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション
Publication of JP2004506723A publication Critical patent/JP2004506723A/ja
Publication of JP2004506723A5 publication Critical patent/JP2004506723A5/ja
Application granted granted Critical
Publication of JP5022554B2 publication Critical patent/JP5022554B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
JP2002521434A 2000-08-24 2001-08-24 アルツハイマー病の生前診断ならびにアミロイド沈着物のインビボ画像化および予防に用いるためのチオフラビン誘導体 Expired - Lifetime JP5022554B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22760100P 2000-08-24 2000-08-24
US60/227,601 2000-08-24
PCT/US2001/026427 WO2002016333A2 (en) 2000-08-24 2001-08-24 Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011266396A Division JP2012102106A (ja) 2000-08-24 2011-12-06 アルツハイマー病の生前診断ならびにアミロイド沈着物のインビボ画像化および予防に用いるためのチオフラビン誘導体

Publications (3)

Publication Number Publication Date
JP2004506723A JP2004506723A (ja) 2004-03-04
JP2004506723A5 JP2004506723A5 (enExample) 2005-12-22
JP5022554B2 true JP5022554B2 (ja) 2012-09-12

Family

ID=22853739

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002521434A Expired - Lifetime JP5022554B2 (ja) 2000-08-24 2001-08-24 アルツハイマー病の生前診断ならびにアミロイド沈着物のインビボ画像化および予防に用いるためのチオフラビン誘導体
JP2011266396A Pending JP2012102106A (ja) 2000-08-24 2011-12-06 アルツハイマー病の生前診断ならびにアミロイド沈着物のインビボ画像化および予防に用いるためのチオフラビン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011266396A Pending JP2012102106A (ja) 2000-08-24 2011-12-06 アルツハイマー病の生前診断ならびにアミロイド沈着物のインビボ画像化および予防に用いるためのチオフラビン誘導体

Country Status (18)

Country Link
US (5) US20020133019A1 (enExample)
EP (2) EP1334091B1 (enExample)
JP (2) JP5022554B2 (enExample)
CN (1) CN1285582C (enExample)
AU (3) AU8670201A (enExample)
BR (1) BRPI0113470B8 (enExample)
CA (1) CA2419420C (enExample)
CY (1) CY1113311T1 (enExample)
DK (2) DK2264018T3 (enExample)
ES (2) ES2395721T3 (enExample)
HU (2) HU230581B1 (enExample)
LT (1) LTC1334091I2 (enExample)
NO (1) NO330176B1 (enExample)
PL (1) PL215711B1 (enExample)
PT (2) PT1334091E (enExample)
RU (1) RU2324686C2 (enExample)
SI (1) SI1334091T1 (enExample)
WO (1) WO2002016333A2 (enExample)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
EP1266884A4 (en) * 2000-03-22 2003-04-23 Bf Res Inst Inc IMAGE DIAGNOSIS PROBE, BASED ON SUBSTITUTED AZOBENZOL OR ITS ANALOGA, FOR DISEASES WHICH ARE ATTRIBUTED TO AMYLOID ACCUMULATION, AND MIXTURES CONTAINING THIS IMAGE
US7297326B2 (en) * 2000-08-21 2007-11-20 The General Hospital Corporation Ocular diagnosis of Alzheimer's disease
US7107092B2 (en) 2000-08-21 2006-09-12 The General Hospital Corporation Methods for diagnosing a neurodegenerative condition
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
RU2324686C2 (ru) * 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
DE60128138T2 (de) * 2000-11-02 2008-01-03 Cornell Research Foundation, Inc. In vivo multiphoton diagnostische detektion und bilddarstellung einer neurodegenerativen erkrankung
WO2002051821A1 (en) * 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
AU2002353739A1 (en) * 2001-11-28 2003-06-10 Astrazeneca Ab Therapeutic compounds
US6774248B2 (en) 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
US7008958B2 (en) 2002-05-21 2006-03-07 Bristol-Myers Squibb Company 2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same
WO2003106439A1 (ja) * 2002-06-12 2003-12-24 株式会社ビーエフ研究所 アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑／びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬
EP1380290A1 (en) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
JPWO2004035522A1 (ja) * 2002-08-30 2006-02-16 株式会社 ビーエフ研究所 プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
DK1587821T6 (da) 2002-12-19 2025-05-26 Scripps Research Inst Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning
GB0229686D0 (en) * 2002-12-20 2003-01-29 Amersham Plc Solid-phase fluorination of benzothiazoles
CA2438032C (en) * 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
PL1611115T3 (pl) * 2003-03-14 2013-01-31 Univ Pittsburgh Commonwealth Sys Higher Education Związki pochodne benzotiazolu, kompozycje i zastosowania
GB0307855D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
EP1631561B1 (en) 2003-05-07 2010-08-18 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
WO2005016384A1 (ja) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
EP1655287A1 (en) * 2003-08-13 2006-05-10 BF Research Institute, Inc. Probe for diseases with amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change
US8236282B2 (en) 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
JP3877754B2 (ja) * 2003-10-30 2007-02-07 株式会社同仁化学研究所 アミロイド親和性化合物
CA2558064A1 (en) * 2004-02-25 2005-09-01 Astellas Pharma Inc. Contrast medium for thrombus formation
BRPI0510260A (pt) 2004-04-27 2007-10-23 Wyeth Corp método para purificar um composto, e, kit farmacêutico
GB0410448D0 (en) 2004-05-11 2004-06-16 Hammersmith Imanet Ltd Purification methods
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
US20080286202A1 (en) * 2004-07-02 2008-11-20 University Of Pittsburgh Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition
DK1771208T3 (da) * 2004-07-02 2013-09-02 Univ Pittsburgh Anvendelse af thioflavin radiomarkerede derivater i amyloid billeddannelse til vurdering af anti-amyloide terapier
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US20090087376A1 (en) * 2004-07-15 2009-04-02 The General Hospital Corporation Heterocyclic Dye Compounds For In Vivo Imaging And Diagnosis Of Alzheimer's Disease
EP1781289A1 (en) 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
BRPI0613525A2 (pt) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
EP2386861A3 (en) 2005-07-13 2012-07-18 Crossbeta Biosciences B.V. Cross-ß structure binding compounds
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
EP1937260A2 (en) * 2005-09-16 2008-07-02 University of Pittsburgh In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein
KR100778888B1 (ko) * 2005-11-29 2007-11-28 재단법인서울대학교산학협력재단 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물
US8022075B2 (en) 2005-11-30 2011-09-20 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
AU2006320556A1 (en) * 2005-12-01 2007-06-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Isotopically-labeled benzothiazole compounds as imaging agents for amyloidogenic proteins
WO2007075595A2 (en) * 2005-12-20 2007-07-05 Vertex Pharmacueticals Incorporated Biofilm assay
US7781187B2 (en) * 2005-12-30 2010-08-24 Corning Incorporated Fluorescent dyes
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
BRPI0707719A2 (pt) 2006-02-10 2011-05-10 Summit Corp Plc uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo
WO2007111179A1 (ja) * 2006-03-28 2007-10-04 Shiga University Of Medical Science 神経難病の画像診断薬
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
EP2023919A4 (en) * 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
JP5238496B2 (ja) 2006-05-19 2013-07-17 日本メジフィジックス株式会社 新規アミロイド親和性化合物
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
CN101501033B (zh) 2006-06-21 2012-08-01 通用电气医疗有限公司 对淀粉状蛋白具有亲和性的化合物
EP2059491A1 (en) 2006-08-03 2009-05-20 Hammersmith Imanet Limited Method for the purification of radiolabelled compounds
CN101595108A (zh) 2006-11-30 2009-12-02 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
CN101668560A (zh) * 2006-12-07 2010-03-10 宾夕法尼亚大学理事会 乙炔衍生物及它们在结合和显像淀粉样斑块中的应用
EP2126609B1 (en) * 2007-01-30 2013-03-27 GE Healthcare Limited Tools for aiding in the diagnosis of neurodegenerative diseases
EP2119458B9 (en) 2007-02-13 2013-08-21 Nihon Medi-Physics Co., Ltd. Method for production of radiation diagnostic imaging agent
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
CN101293878B (zh) * 2007-04-25 2010-12-15 中国科学院上海应用物理研究所 苯并噻唑苯胺类化合物及其制备方法和应用
AU2008285289A1 (en) 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
US8916131B2 (en) * 2007-08-30 2014-12-23 Ge Healthcare Limited Radiopharmaceutical composition
TW200918102A (en) * 2007-10-24 2009-05-01 Nihon Mediphysics Co Ltd Novel compound having affinity for amyloid
CN101903383A (zh) 2007-10-26 2010-12-01 日本医事物理股份有限公司 对淀粉样蛋白具有亲和性的新化合物
KR20100101577A (ko) 2007-10-30 2010-09-17 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법
CA2704168A1 (en) * 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
US20090123373A1 (en) * 2007-11-05 2009-05-14 Yanming Wang Amyloid-imaging agents
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
US8530483B2 (en) 2008-05-30 2013-09-10 Merck Sharp & Dohme Corp. Substituted azabenzoxazoles
AU2009253046A1 (en) * 2008-05-30 2009-12-03 Foster Wheeler Energia Oy Method of and system for generating power by oxyfuel combustion
EP2296474A1 (en) * 2008-05-30 2011-03-23 Merck Sharp & Dohme Corp. Novel substituted indoles
ES2714453T3 (es) 2008-06-09 2019-05-28 Univ Muenchen Ludwig Maximilians Fármacos para inhibir la agregación de proteínas implicadas en enfermedades relacionadas con enfermedades neurodegenerativas y/o agregación de proteínas
US20100099609A1 (en) * 2008-07-28 2010-04-22 Buck Institute For Age Research eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
WO2010039815A1 (en) 2008-09-30 2010-04-08 Case Western Reserve University Molecular probes for imaging of myelin
KR101155403B1 (ko) * 2008-11-06 2013-12-20 서울대학교산학협력단 플루오린이 도입된 벤조타이아졸 유도체, 이의 제조방법 및 이를 이용한 알츠하이머 질환 진단용 영상화제
US20100129290A1 (en) * 2008-11-26 2010-05-27 I.S.T. Corporation Smart contrast agent and detection method for detecting transition metal ions
CN101598703B (zh) * 2009-07-03 2012-08-22 中国人民解放军第三军医大学第一附属医院 dGTpase蛋白在制备用于鉴别诊断唐氏胎儿药物中的应用
FR2948685A1 (fr) * 2009-07-30 2011-02-04 Biomerieux Sa Nouveaux substrats
US20110081428A1 (en) * 2009-09-16 2011-04-07 The Buck Institute For Age Research Use of thioflavin-like compounds to increase life span and/or health span
DE102010045797A1 (de) 2010-09-20 2012-03-22 Klinikum Darmstadt Gmbh Verbindungen für die Diagnostik neurodegenerativer Erkrankungen am Riechepithel
WO2012041292A2 (de) 2010-09-20 2012-04-05 Klinikum Darmstadt Gmbh Verbindungen für die diagnostik neurodegenerativer erkrankungen an der retina
KR20140040722A (ko) 2011-05-20 2014-04-03 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
IN2014DN00185A (enExample) 2011-06-24 2015-07-10 Nihon Mediphysics Co Ltd
JPWO2013027694A1 (ja) * 2011-08-24 2015-03-19 国立大学法人京都大学 コンフォメーション病診断用分子イメージングプローブ
WO2013038351A1 (en) 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
CN102526765B (zh) * 2011-12-31 2014-07-30 郑州泰基鸿诺药物科技有限公司 一种Aβ斑块显像剂及其制备方法
KR20130111082A (ko) * 2012-03-30 2013-10-10 한미약품 주식회사 베타-아밀로이드 피브릴 형성 저해 효능을 갖는 아미노스티릴벤조퓨란 화합물 및 이를 함유하는 약학 조성물
EP2890700B1 (de) * 2012-08-28 2017-12-13 Eberhard Karls Universität Tübingen Medizinische Fakultät Halogenierte benzoxazine und ihre verwendung
DK2890700T3 (en) 2012-08-28 2018-03-12 Univ Tuebingen Medizinische Fakultaet HALOGENATED BENZOXAZINES AND THEIR USE
JP5422782B1 (ja) 2012-12-21 2014-02-19 独立行政法人放射線医学総合研究所 脳内に蓄積したタウタンパク質をイメージングするための新規化合物
US9246108B2 (en) 2012-12-28 2016-01-26 Dow Global Technologies Llc Quinoline-benzoxazole derived compounds for electronic films and devices
EP2958596B1 (en) 2013-02-15 2019-12-04 Case Western Reserve University Psma ligands and uses thereof
KR101770532B1 (ko) 2013-09-26 2017-08-22 에프. 호프만-라 로슈 아게 이미징 수단으로서의 이미다조[1,2-a]피리딘-7-아민
WO2015051188A1 (en) 2013-10-02 2015-04-09 Washington University Heterocyclic molecules for biomedical imaging and therapeutic applications
US11844774B2 (en) 2014-04-24 2023-12-19 Omoidesouzou Co., Ltd. Amyloid fiber formation limiter or inhibitor
CN104059028B (zh) * 2014-06-06 2020-10-16 北京智博高科生物技术有限公司 与Aβ斑块具有亲和力的含手性侧链取代的氟代2-芳基苯并杂环化合物、其制备方法及应用
JP6498412B2 (ja) * 2014-10-17 2019-04-10 国立大学法人群馬大学 新規チオフラビンｔ誘導体及びその利用
US9842938B2 (en) 2015-03-24 2017-12-12 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device and display device including semiconductor device
EP3426309B1 (en) 2016-03-09 2022-05-04 Case Western Reserve University Radioligands for myelin
EP3426653B1 (en) 2016-03-11 2021-12-15 AC Immune SA Bicyclic compounds for diagnosis and therapy
US10675365B2 (en) 2016-09-29 2020-06-09 Korea Atomic Energy Research Institute Curcumin derivative, method for producing same, and photo-acoustic imaging agent comprising same for detecting beta-amyloid plaque
MX2020010999A (es) 2018-04-18 2021-01-20 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
US11167283B2 (en) 2018-05-04 2021-11-09 University Of South Carolina Dot blot box and use thereof
CN112384517B (zh) 2018-05-09 2023-07-14 新旭生技股份有限公司 杂芳基化合物及其用途
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
ES3032326T3 (en) * 2019-01-31 2025-07-17 Spinogenix Inc Solid forms of a promoter of spinogenesis
PE20220562A1 (es) 2019-07-24 2022-04-13 Constellation Pharmaceuticals Inc Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
CA3161455A1 (en) 2019-11-13 2021-05-20 Aprinoia Therapeutics Limited Compounds for degrading tau protein aggregates and uses thereof
KR102426160B1 (ko) 2020-07-13 2022-07-29 (주)바이오액츠 알츠하이머 진단용 신규 형광화합물 및 이의 제조방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA241942A (en) 1924-08-05 Martinetto Vittorio Asynchronous machine
US2715629A (en) * 1952-07-16 1955-08-16 Du Pont Sulfonic acid derivatives of 2-(4'-dialkylaminophenyl)-benzothiazole
NL126227C (enExample) * 1958-08-22
DE3148291A1 (de) 1981-12-05 1983-06-09 Basf Ag, 6700 Ludwigshafen Harnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
DE3307364A1 (de) * 1983-03-02 1984-09-06 Hoechst Ag, 6230 Frankfurt Zweikomponenten-diazontypiematerial
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
DE3874187T2 (de) * 1987-04-08 1993-04-08 Salutar Inc Nachweis fuer amyloidose und alzheimer'sche krankheit sowie reagens hierfuer.
US4933156A (en) * 1987-04-08 1990-06-12 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
US5297562A (en) 1991-04-01 1994-03-29 President And Fellows Of Harvard College Method for detecting and treating Alzheimer's disease
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
GB9317949D0 (en) * 1993-08-28 1993-10-13 Stevens Malcolm F G Benzothiazole compounds
JPH09511492A (ja) 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
US6417178B1 (en) 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
GB9503946D0 (en) * 1995-02-28 1995-04-19 Cancer Res Campaign Tech Benzazole compounds
EP1110945A3 (en) 1995-05-01 2003-05-07 University Of Pittsburgh Azocompounds for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
WO1997026919A2 (en) * 1996-01-24 1997-07-31 Warner-Lambert Company Method of imaging amyloid deposits
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
AU5354398A (en) 1996-11-22 1998-06-10 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions compri sing same, and methods for inhibiting beta-amyloid peptide release and/or it s synthesis by use of such compounds
US6348478B1 (en) * 1997-11-20 2002-02-19 Teijin Limited Biphenylamidine derivatives
AU1089900A (en) 1998-06-30 2000-01-24 Kevin Mcclung Controlled-penetration projectile
JP3820037B2 (ja) * 1998-11-05 2006-09-13 三井化学株式会社 光記録媒体
GB9919673D0 (en) * 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
RU2324686C2 (ru) 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
WO2002051821A1 (en) 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
CA2444214A1 (en) * 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
GB0229686D0 (en) 2002-12-20 2003-01-29 Amersham Plc Solid-phase fluorination of benzothiazoles
PL1611115T3 (pl) * 2003-03-14 2013-01-31 Univ Pittsburgh Commonwealth Sys Higher Education Związki pochodne benzotiazolu, kompozycje i zastosowania
US8236282B2 (en) * 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
DK1771208T3 (da) * 2004-07-02 2013-09-02 Univ Pittsburgh Anvendelse af thioflavin radiomarkerede derivater i amyloid billeddannelse til vurdering af anti-amyloide terapier
US8138360B2 (en) * 2005-10-11 2012-03-20 University of Pittsburgh—of the Commonwealth System of Higher Education Isotopically-labeled benzofuran compounds as imaging agents for amyloidogenic proteins

Also Published As

Publication number Publication date
NO20030860L (no) 2003-04-24
LTPA2015001I1 (lt) 2015-02-25
EP1334091B1 (en) 2012-09-19
US9833458B2 (en) 2017-12-05
SI1334091T1 (sl) 2013-01-31
EP2264018A3 (en) 2012-04-25
CN1535268A (zh) 2004-10-06
ES2536449T3 (es) 2015-05-25
US7351401B2 (en) 2008-04-01
CN1285582C (zh) 2006-11-22
RU2324686C2 (ru) 2008-05-20
HU230581B1 (hu) 2017-01-30
EP1334091A2 (en) 2003-08-13
US20150190400A1 (en) 2015-07-09
HUP1500560A2 (en) 2003-12-29
WO2002016333A3 (en) 2002-05-30
AU2008202626A1 (en) 2008-07-03
US20080154042A1 (en) 2008-06-26
US20120095235A1 (en) 2012-04-19
AU8670201A (en) 2002-03-04
DK1334091T3 (da) 2012-10-15
US20020133019A1 (en) 2002-09-19
PL360550A1 (en) 2004-09-06
NO330176B1 (no) 2011-02-28
HU230375B1 (hu) 2016-03-29
DK2264018T3 (en) 2015-05-11
PT1334091E (pt) 2013-01-07
JP2004506723A (ja) 2004-03-04
US20050043377A1 (en) 2005-02-24
ES2395721T3 (es) 2013-02-14
EP2264018B1 (en) 2015-02-11
NO20030860D0 (no) 2003-02-24
HK1058041A1 (en) 2004-04-30
AU2008202626B2 (en) 2010-02-04
BR0113470A (pt) 2003-12-30
WO2002016333A2 (en) 2002-02-28
CA2419420A1 (en) 2002-02-28
EP2264018A2 (en) 2010-12-22
JP2012102106A (ja) 2012-05-31
AU2001286702B2 (en) 2008-03-13
HK1146725A1 (en) 2011-07-08
CA2419420C (en) 2011-08-02
LTC1334091I2 (lt) 2018-05-25
CY1113311T1 (el) 2016-04-13
AU2008202626B9 (en) 2010-02-11
PL215711B1 (pl) 2014-01-31
BRPI0113470B1 (pt) 2019-04-16
BRPI0113470B8 (pt) 2021-05-25
HUP0302956A2 (hu) 2003-12-29
HUP0302956A3 (en) 2006-05-29
PT2264018E (pt) 2015-06-03

Similar Documents

Publication Publication Date Title
US7351401B2 (en) Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition
US10137210B2 (en) Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
AU2001286702A1 (en) Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
US20100143251A1 (en) Compounds and amyloid probes thereof for therapeutic and imaging uses
US8343457B2 (en) Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies
RU2440995C2 (ru) Производные бензотиазола, фармацевтическая композиция, обладающая свойством связывать амилоид, и способ детекции отложений амилоида у млекопитающего
HK1058041B (en) Thioflavin derivatives and their use in diagnosis and therapy of alzheimer's disease
HK1146725B (en) Thioflavin derivatives for use in the diagnosis of alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080411

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120523

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120618

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5022554

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150622

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term